ClinicalTrials.gg
RecruitingNCT06716931DM2Updated Oct 8, 2026

Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

An interventional study of Exercise and Exercise in Myotonic Dystrophy 2, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 8, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
19th of 22
24 · median 46
Started
2025
with 5 others
No phase
Only one
of the 43
Primary completion
2027-12
later than 10 of 26 live
Registered
32nd of 43
by date
Lead sponsor
5 of 43
Massachusetts General Hospital

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 19th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2025, is the only one with no phase, reaches primary completion later than 10 of the 26 other live ones, and was the 32nd registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

An exercise regimen (PRIME: Proximal Resistance In-House Movement Exercise) has been designed for patients with myotonic dystrophy type 2 (DM2). The hypothesis is that this patient-friendly physical therapist (PT)-guided exercise program associates with improved functional capacity and muscle composition in DM2 in this two-period two-sequence cross-over study. Thus, participant will be randomized to one of the three possible groups. Participants in GROUP A will perform exercise routine virtually under the direct supervision of a physical therapist once a week and another session on their own for the first three months, then they will continue with same exercise routine at home for the last 3 months on their own. Participants in GROUP B will perform exercise routine virtually under the direct supervision of a physical therapist twice a week for the first three months, then they will continue with same exercise routine at home for the last 3 months on their own. Participants in GROUP C will perform exercise routine on their own during the first 3 months, then they will perform exercise routine virtually under the direct supervision of a physical therapist. Each group will include around 8 participants. Duration of the study is 6 months. In addition to exercise sessions, participants will have evaluation of their strength, motor function and muscle composition at three time points: initiation, 3 months and completion of the study at 6 months. Muscle composition will be assessed by electrical impedance myography which is a portable, non-invasive, painless and non-radiation tool that applies a weak high multifrequency electrical current to the examined muscle and allows to obtain information about its composition.

03

Conditions studied

  • Myotonic Dystrophy 2

Keywords

  • exercise
  • physical therapist
  • myotonic dystrophy type 2
  • electrical impedance myography
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with genetically confirmed myotonic dystrophy 2 (DM2) who are ≥18 and ≤ 70 years old.
  • Patients are ambulatory without need of any assistance or device.
  • Patients have a normal within the 3 months prior to Screening visit (of note, patients with DM2 are recommended to have routine ECG as part of patient care. So, this ECG will be done as part of patient care).
  • (BMI) ≥20 and ≤30.

Exclusion criteria

Exclusion Criteria:

  • Subjects younger than 18 years old or older than 70 years old.
  • Inability or unwillingness of the subject to give written .
  • Subjects with pacemaker.
  • Blood pressure \<90/50 mmHg or >160 mmHg/90 mmHg at Screening visit
  • Resting heart rate of \<60 or >100 beats/minute at Screening visit.
  • Any fall within the last six months.
  • Any history of syncopal episodes or family history of sudden death.
  • Patients who are pregnant or plan to become pregnant. A urine pregnancy test will be performed at visit 1 and 3 for women of childbearing age. If positive or if subject is planning to become pregnant, subject will be not eligible for the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Group A

    Exercise under the supervision of physical therapist in clinic during the first 3 months, then self-directed exercise routine for the last 3 months

    Other: Exercise

  • Active comparator
    Group B

    Exercise under the supervision of physical therapist virtually during the first 3 months, then self-directed exercise routine for the last 3 months

    Other: Exercise

  • Active comparator
    Group C

    Self-directed exercise routine for the first 3 months, then exercise routine under the supervision of physical therapist virtually during the last 3 months

    Other: Exercise

Interventions

  • OtherExercise

    A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated. In person exercise supervised by physical therapist and then self-directed exercise in Group A

  • OtherExercise

    Exercise virtually supervised by physical therapist and then self-directed for group B

  • OtherExercise

    Self-directed and virtually supervised exercise by physical therapist for Group C

06

What researchers measure

Primary outcomes

  1. Manual Muscle Test (MMT)

    Score of manual muscle strength test scale. This is a strength exam at bedside of muscle groups

    Time frame: From enrollment to the end of treatment at 6 months

  2. Six-minute walking test

    Distance in meters that subject can walk in six minutes

    Time frame: From enrollment to the end of treatment at 6 months

Secondary outcomes

  1. Quantitative myometry

    Muscle dynamometry of different muscle groups measured in kilograms

    Time frame: From enrollment to the end of treatment at 6 months

  2. Muscle resistance/reactance measures in ohms

    using electrical impedance myography, resistance and reactance measures in ohms will be obtained simultaneously from each examined muscle

    Time frame: From enrollment to the end of treatment at 6 months

Other outcomes

  1. Time up to go

    Time in seconds from standing up, walk 3 meters, come back and sit again.

    Time frame: From enrollment to the end of treatment at 6 months

  2. 10 meter walk testing

    Time in seconds during a 10-meter walk.

    Time frame: From enrollment to the end of treatment at 6 months

  3. Five times sit to stand

    Time in seconds to complete 5 times sit to stand.

    Time frame: From enrollment to the end of treatment at 6 months

  4. Functional gait assessment (FGA)

    Assessment of balance using a scale (0-30) while walking and performing motor tasks.

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 of 1 sites recruiting
  • Neuromuscular Diagnostic Center. Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 26 interventional studies with no phase under Myotonic Dystrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Dec 4, 2024
StartActual
Mar 4, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: z•••@mgh.harvard.edu · •••3642→b•••@mgh.harvard.edu · •••3642. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Neuromuscular Diagnostic Center. Massachusetts General Hospital · Boston, United StatesContact z•••@mgh.harvard.edu · •••5297→b•••@mgh.harvard.edu · •••5297Contact added b•••@mgh.harvard.edu · •••3642
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Contact Study contact changed: z•••@mgh.harvard.edu · •••3642→b•••@mgh.harvard.edu · •••3642. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Neuromuscular Diagnostic Center. Massachusetts General Hospital · Boston, United StatesContact z•••@mgh.harvard.edu · •••5297→b•••@mgh.harvard.edu · •••5297Contact added b•••@mgh.harvard.edu · •••3642
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06716931
Responsible party
Paloma Gonzalez Perez, MD, PhD (Neurologist, Massachusetts General Hospital) — Principal investigator
First posted
Dec 4, 2024
Start date
Mar 4, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Blanca Escauriaza, RN
Contact
bescauriaza@mgh.harvard.edu
617-726-3642

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion